Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07052383Phase 1Recruiting

Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas

Role: lead

NCT06482905Phase 1Recruiting

Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.

Role: lead

NCT07485504Phase 1Not Yet Recruiting

Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies

Role: lead

NCT07231081Phase 1Recruiting

Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors

Role: lead

All 4 trials loaded